Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572299 | 0.94 | MEN1 (0.51) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL16572359 | 0.93 | MEN1 (0.50) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL16572095 | 0.91 | MEN1 (0.56) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL873480 | 0.88 | CYP1A2 (0.57) | — | |
| SCHEMBL8707341 | 0.87 | HRH3 (0.53) | — | |
| SCHEMBL25018426 | 0.84 | MEN1 (0.46) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL9036035 | 0.83 | HTR2A (0.62) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL874547 | 0.82 | HRH3 (0.70) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3244586 | 0.82 | HTR2A (0.65) | MEN1USP2ALDH1A1LMNACYP3A4 | |
| SCHEMBL22919760 | 0.81 | MAPK1 (0.48) | MEN1USP2ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260398-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099764-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | MEN1 1650/4885USP2 4328/4885ALDH1A1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.